This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Juventas Therapeutics, Inc.

Drug Names(s): ACRX-100, MyoCell SDF-1

Description: JVS-100 is a plasmid that encodes Stromal Cell-derived Factor-1 (SDF-1). SDF-1 is thought to inhibit cell death, recruit stem cells that repair tissue, and promote blood flow. JVS-100 is injected into multiple sites of the left ventricular heart muscle using a percutaneous needle injection catheter.

Deal Structure: JVS-100 was originally developed by AcelleRX Therapeutics. AcelleRX changed its name to Juventas Therapeutics.

JVS-100 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug